FDA 483 OBSERVATION · #154 OF 1,923 MOST-CITED
Training , Education , Experience overall
FDA cited this observation 200 times across 189 firms in recent inspections. Below: how it breaks down by program area and fiscal year, and real examples of how FDA worded it on Form FDA 483.
What this grouping is not
An observation-type page groups FDA’s published citation records. The grouping, the compliance steps and the root causes are SPEQ synthesis, not an FDA classification of any citation, and a count measures what FDA published rather than risk.
What this observation means, and how to comply
SPEQ's practitioner reading of this finding. The regulatory basis is a cited fact; the interpretation, compliance steps, and root causes are SPEQ synthesis — not an FDA classification of the citation.
Drug CGMP requires each person engaged in the manufacture, processing, packing, or holding of a drug product to have the education, training, and experience — or a combination — to perform their assigned functions, with training in current GMP conducted by qualified individuals on a continuing basis.
Why FDA writes it — FDA cites this when personnel lack documented qualification or ongoing CGMP training, because in a validated pharmaceutical operation an inadequately trained operator or analyst is a root cause of deviations, data-integrity lapses, and product failures.
- Establish job descriptions defining the education, training, and experience each drug-manufacturing role requires.
- Deliver initial and continuing CGMP training specific to each person’s functions, conducted by qualified trainers.
- Document each employee’s qualifications and training history and keep it current with role and procedure changes.
- CGMP training treated as a one-time hire event rather than the continuing program the rule requires.
- No documented tie between an individual’s education, training, and experience and the specific functions they are assigned.
How to close this finding — and stop it recurring
What this observation is associated with
Firms cited for this observation also appear in FDA compliance actions — warning letters, injunctions, or seizures — at 5.1× the rate of the average FDA-cited firm (39.1% vs 7.8%), across 189 FEI-matched firms.
This is an association, not causation, and reflects co-occurrence in FDA's records — not a claim that the observation caused or preceded the action.
How FDA worded it — real examples
Employees engaged in the processing of a drug product lack the training required to perform their assigned functions.
Employees engaged in the processing of a drug product lack the training required to perform their assigned functions.
Employees engaged in the processing of a drug product lack the training required to perform their assigned functions.
Employees engaged in the manufacture, processing, packing and holding of a drug product lack the training required to perform their assigned functions.
Employees engaged in the packing of a drug product lack the training required to perform their assigned functions.
Employees engaged in the manufacture of a drug product lack the training required to perform their assigned functions.
Related SPEQ references
Where to read the requirements behind this observation area on SPEQ. These are SPEQ's topic and audience pages — not an FDA classification of the citation.
Examples are a representative sample of FDA's published inspection observations. Open the 483 observation explorer →